Ubs Group Ag Otonomy, Inc. Transaction History

Ubs Group Ag

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.72 - $2.47 $16,685 - $23,961	-9,701 Reduced 82.91%	2,000 $5,000
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.31 $19,098 - $26,105	11,301 Added 2825.25%	11,701 $24,000
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $12,119 - $21,854	-9,934 Reduced 96.13%	400 $1,000
Q2 2021 Aug 13, 2021	BUY	$2.06 - $2.67 $17,942 - $23,255	8,710 Added 536.33%	10,334 $23,000
Q1 2021 May 12, 2021	BUY	$2.49 - $6.23 $3,047 - $7,625	1,224 Added 306.0%	1,624 $4,000
Q3 2020 Nov 12, 2020	SELL	$3.16 - $4.36 $2,445 - $3,374	-774 Reduced 65.93%	400 $2,000
Q2 2020 Jul 31, 2020	SELL	$1.87 - $3.84 $510 - $1,048	-273 Reduced 18.87%	1,174 $4,000
Q1 2020 May 01, 2020	BUY	$1.58 - $4.06 $2,286 - $5,874	1,447 New	1,447 $3,000
Q4 2019 Feb 14, 2020	SELL	$2.13 - $3.83 $6,217 - $11,179	-2,919 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.12 - $2.86 $2,510 - $3,386	1,184 Added 68.24%	2,919 $7,000
Q2 2019 Aug 14, 2019	SELL	$2.35 - $3.09 $49 - $64	-21 Reduced 1.2%	1,735 $5,000
Q1 2019 May 14, 2019	BUY	$1.8 - $2.97 $3,160 - $5,215	1,756 New	1,756 $5,000
Q4 2018 Feb 14, 2019	SELL	$1.51 - $2.93 $1,094 - $2,124	-725 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.95 $228 - $347	88 Added 13.81%	725 $2,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $4.75 $2,356 - $3,025	637 New	637 $2,000
Q4 2017 Feb 14, 2018	SELL	$2.8 - $5.55 $2,433 - $4,822	-869 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$3.2 - $20.8 $2,870 - $18,657	-897 Reduced 50.79%	869 $3,000
Q2 2017 Aug 14, 2017	BUY	N/A	705 Added 66.45%	1,766 $33,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,061	1,061 $13,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.